Summit Therapeutics

1. HARMONi-GI1 readout2026HARMONi-GI1 readout, 2026, notable
2. ivonescimab NSCLC interim2H 2026ivonescimab NSCLC interim, 2H 2026, material
3. HARMONi-GU1 corporate update4Q 2026HARMONi-GU1 corporate update, 4Q 2026, routine
4. ivonescimab NSCLC PDUFA dateNov 14, 2026ivonescimab NSCLC PDUFA date, Nov 14, 2026, thesis-defining
5. ivonescimab NSCLC FDA decisionNov 14, 2026ivonescimab NSCLC FDA decision, Nov 14, 2026, thesis-defining
6. Share authorization increase financingDec 31, 2026Share authorization increase financing, Dec 31, 2026, routine
7. HARMONi-3 non-squamous readout1H 2027HARMONi-3 non-squamous readout, 1H 2027, notable
8. AstraZeneca preferred stock lock-up corporatelate 2027AstraZeneca preferred stock lock-up corporate, late 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.